WHO, EIB Global €10m Lebanon grant targets 50,000 chronic-care patients

World Health Organization (WHO) and EIB Global signed a €10 million grant on 6 March 2025 to rebuild Lebanon's public health laboratory capacity and support medicines access for more than 50,000 chronic-disease patients.

For UAE healthcare executives, the takeaway is operational risk: Lebanese patient flows can affect referrals, medicine continuity, lab histories and family-funded chronic care in Dubai and Abu Dhabi.

What the grant covers

The WHO notice said Dr Tedros Adhanom Ghebreyesus, WHO Director-General, and Thomas Östros, EIB Vice-President, signed the agreement at the EIB Group Forum in Luxembourg. The funding will re-establish Lebanon's Central Public Health Laboratory and provide medicines and healthcare support for patients with diabetes, cardiovascular disease and cancer.

The EIB statement identified several functions that matter to hospital groups, diagnostic networks and pharmacy operators with regional patient exposure:

• Central Public Health Laboratory testing for emergency infectious diseases.
• Pathogen confirmation during outbreak investigations.
• Testing of all blood donations for transfusion safety.
• Support for primary healthcare centres, including reproductive health services.
• Funding through the Economic Resilience Initiative Fund, created by EIB in 2017.

Why UAE operators should watch it

The grant is small against Gulf healthcare balance sheets, but its target matters because chronic-care disruption creates repeat demand. EIB Global said the initiative will reach more than 50,000 people with diabetes, cardiovascular disease and cancer, while Lebanon hosted about 1.5 million Syrian refugees and around 200,000 Palestinian refugees.

Dubai Health Authority (DHA) data show why cross-border demand can land quickly in private-sector capacity. DHA said on 5 June 2024 that it issued licences to more than 150 healthcare facilities and 800 healthcare professionals in the first quarter of 2024, and renewed licences for 1,122 healthcare facilities.

The relevant question for a UAE operator is specific: can the organisation identify patients whose medications, lab records or oncology protocols depend on Lebanese providers? For COOs, that means checking intake forms, medication reconciliation and lab-result provenance. For CFOs, it means separating charity-care exposure from commercially priced second opinions and chronic-care packages.

UAE regulatory context

Lebanon remains outside the regulatory scope of DHA, Department of Health Abu Dhabi (DOH) and Ministry of Health and Prevention (MOHAP). The Lebanon grant does not create a 2025 compliance deadline in the UAE, but it gives regional operators a practical checklist tied to referrals, laboratories and medicine supply.

MOHAP cites about 4,500 new cancer cases in the UAE each year on the official government portal's chronic disease page. DOH publishes Abu Dhabi health statistics through its open data dashboards. DHA regulates Dubai facilities and licensing, including the private-sector base that receives regional patients.

Hospital groups should map Lebanese referral relationships, confirm which laboratories are used for outsourced or historical test results, and review substitute medicine protocols for diabetes, cardiovascular disease and oncology. CIOs should check whether patient records from Lebanon can be ingested as structured documents or only as scanned PDFs.

The next signal is execution. If WHO and EIB Global restore the Central Public Health Laboratory during 2025, UAE providers may see better verified lab histories for Lebanese patients. If medicine scarcity persists, Dubai and Abu Dhabi outpatient groups could face more chronic-care demand from self-pay patients seeking continuity rather than new diagnoses.